Use of Precision Medicine Molecular Profiling of Baseline Tumor Specimen May Not Benefit Outcomes in Children With Relapsed or Refractory Pediatric Sarcomas

Clin Pharmacol Ther. 2017 Mar;101(3):328-330. doi: 10.1002/cpt.599.

Abstract

Given the poor prognosis of pediatric patients with relapsed or refractory sarcomas, discovery and implementation of innovative approaches and tools to guide therapy are urgent needs. This retrospective pilot study evaluated the impact of relapse and refractory therapies aligned with molecular characterization of biopsies collected at the time of primary diagnosis.

MeSH terms

  • Antineoplastic Agents* / administration & dosage
  • Antineoplastic Agents* / adverse effects
  • Biopsy
  • Child
  • Child, Preschool
  • Co-Repressor Proteins / genetics
  • DNA Topoisomerases, Type I
  • Drug Resistance, Neoplasm
  • Female
  • Humans
  • Kaplan-Meier Estimate
  • Male
  • Molecular Diagnostic Techniques / methods
  • Molecular Targeted Therapy* / methods
  • Molecular Targeted Therapy* / statistics & numerical data
  • Pharmacogenomic Testing / methods
  • Pilot Projects
  • Prognosis
  • Sarcoma* / drug therapy
  • Sarcoma* / genetics
  • Sarcoma* / mortality
  • Sarcoma* / pathology
  • Secondary Prevention / methods*
  • Treatment Outcome
  • Tubulin / genetics

Substances

  • Antineoplastic Agents
  • Co-Repressor Proteins
  • TLE3 protein, human
  • TUBB3 protein, human
  • Tubulin
  • DNA Topoisomerases, Type I
  • TOP1 protein, human